Accessibility Menu
Microba Life Sciences logo

Microba Life Sciences(ASX) MAP

Market CapA$34.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-85%
5 YearN/A
1 Year-44%
1 Month+17%
A$0.05
+0.00%
+0.00Today
Microba Life Sciences last closing stock price
MetricPriceDate
Last closeAUD 0.052026-08-13
Microba Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.04%AUD 0.052026-08-06
1 month+17.07%AUD 0.042026-07-14
3 month-37.66%AUD 0.082026-05-14
Year to date-36.84%AUD 0.082025-12-31
1 year-43.53%AUD 0.092025-08-13
3 year-87.69%AUD 0.392023-08-14
Since inception-85.47%AUD 0.332022-04-05

Microba Life Sciences Financials at a Glance

Market Cap

A$34.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$31.81M

Net Income (TTM)

-A$33.95M

EPS (TTM)

-A$0.04

P/E Ratio

-1.25

Dividend

A$0.00

Beta (Volatility)

-0.11 (Low)

Price

A$0.05

Volume

2,884

Open

A$0.05

Previous Close

A$0.05

Daily Range

A$0.05 - A$0.05

52-Week Range

A$0.04 - A$0.11

Estimated Earnings Date

Sep 1, 2026

MAP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Microba Life Sciences

Microba Life Sciences Limited is a Brisbane-based company specializing in advanced microbiome testing and analytical services. Established in 2017, the company serves clinicians, consumers, and researchers across various international markets, including Australia, Europe, and the United States.

Products and Services
  • Microbiome testing for clinical and consumer applications
  • Pathology, therapeutic, and diagnostic solutions
  • Data-driven therapeutics platform for microbial cell therapies
Growth Outlook
  • Expansion into key international markets is underway
  • Innovative therapies targeting inflammatory bowel disease are in development
  • Strong demand for microbiome-related diagnostics is anticipated
Financial Highlights
  • Recent quarterly revenue of 7.32 million AUD shows growth potential
  • Cash reserves of 11.27 million AUD provide operational stability
  • Trailing twelve months (TTM) revenue of 30.5 million AUD indicates upward trend
Microba Life Sciences Limited is positioned at the forefront of microbiome research and diagnostics, leveraging its comprehensive databank to drive innovation in therapeutic solutions. The company's focus on developing monoclonal microbial cell therapies aims to address significant health challenges, including inflammatory bowel disease and cancer treatment. With a solid cash position and increasing revenue, Microba is well-equipped to capitalize on the growing interest in microbiome science and its applications in healthcare. The ongoing expansion into international markets further enhances the company's growth prospects, making it an intriguing option for investors interested in the healthcare sector.
AI Generated • Jul 24, 2026

Industry

Healthcare Providers and Services

CEO

Luke Reid, PhD

Headquarters

Brisbane, QLD 4000, AU

MAP Financials

Key Financial Metrics (TTM)

Gross Margin

-19.87%

Operating Margin

-144.16%

Net Income Margin

-132.53%

Return on Equity

-63.04%

Return on Capital

-68.89%

Return on Assets

-45.56%

Earnings Yield

-80.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$34.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

717.12M

Volume

2.88K

Avg. Volume

684.45K

Financials (TTM)

Gross Profit

-A$3.31M

Operating Income

-A$41.23M

EBITDA

-A$37.78M

Operating Cash Flow

-A$21.71M

Capital Expenditure

-A$3.18M

Free Cash Flow

-A$24.88M

Cash & ST Invst.

A$11.27M

Total Debt

A$3.31M

Microba Life Sciences Performance Analysis

Microba Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 4,688,645N/A
20232023-06-30AUD 5,420,13615.6%
20242024-06-30AUD 12,090,055123.1%
20252025-06-30AUD 15,669,08929.6%
Microba Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30169.4%
Q22024-12-30-8.3%
Q42025-06-30-6.2%
Q22025-12-31-3.5%
Microba Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.04N/A
20232023-06-30AUD -0.04-3.5%
20242024-06-30AUD -0.0527.6%
20252025-06-30AUD -0.03-31.5%
Microba Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3038.8%
Q22024-12-3032.3%
Q42025-06-30-59.4%
Q22025-12-3111.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$7.32M

+123.7%

Gross Profit

-A$6.58M

-49.3%

Gross Margin

-89.85%

N/A

Market Cap

A$34.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$430.27K

N/A

Employees

80

N/A

Net Income

-A$10.56M

+8.1%

EBITDA

-A$8.70M

+16.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$11.27M

-59.8%

Total Debt

A$3.31M

+140.2%

Accounts Receivable

A$2.14M

-81.0%

Inventory

A$2.06M

+0.1%

Long Term Debt

A$1.79M

+249.7%

Short Term Debt

A$1.53M

+75.8%

Return on Assets

-45.56%

N/A

Return on Invested Capital

-63.24%

N/A

Free Cash Flow

-A$5.89M

+55.7%

Operating Cash Flow

-A$5.70M

+50.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RHY.AXRhythm Biosciences Limited
A$0.08-1.23%
IIQ.AXINOVIQ Ltd
A$0.19+0.00%
NXS.AXNext Science Limited
A$0.15+0.00%
EMD.AXEmyria Limited
A$0.05+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About MAP

What is the current price of Microba Life Sciences?

Microba Life Sciences is trading at A$0.05 per share.

What is the 52-week range for Microba Life Sciences?

Over the past 52 weeks, Microba Life Sciences has traded between A$0.04 and A$0.11.

How much debt does Microba Life Sciences have?

As of the most recent reporting period, Microba Life Sciences reported total debt of A$3.23M.

How much cash does Microba Life Sciences have on hand?

Microba Life Sciences reported A$11.74M in cash and cash equivalents in its most recent financial results.

What is Microba Life Sciences’s dividend yield?

Microba Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.